Antibiotic antibiotic therapy. The antibiotic treatment may select for bacterial strains with physiologically or genetically enhanced capacity to survive high doses of antibiotics. Under certain conditions, it may result in preferential growth of resistant bacteria, while growth of susceptible bacteria is inhibited by the drug. For example, antibacterial selection for strains having previously acquired antibacterial-resistance genes was demonstrated in 1943 by the Luria–Delbrück experiment. Antibiotics such as penicillin and erythromycin, which used to have a high efficacy against many bacterial species and strains, have become less effective, due to the increased resistance of many bacterial strains. Resistance may take the form
Antibiotic Resistance Lab Network Antibiotic Resistance Lab Network The Antibiotic Resistance Lab Network (ARLN) is a group of laboratories of the United States Centers for Disease Control and Prevention established to supplement the work of local and state public health laboratories in the identification and research of antibiotic resistance. It was created as part of the CDC's "National Action Plan for Combating Antibiotic Resistant Bacteria". The network is part of the National Center for Emerging and Zoonotic Infectious Diseases. Laboratories in this network cover seven regions and are located in Maryland, Minnesota, New York, Tennessee, Texas, Washington, and Wisconsin, as part of their state